Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: Reversal after lipid-lowering therapy by atorvastatin

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 3, 2000, Pages 744-750

  De Man, Frits H ^a   Weverling Rijnsburger, Annelies W E ^a   Van Der Laarse, Arnoud ^a   Smelt, Augustinus H M ^a   Jukema, J Wouter ^a   Blauw, Gerard J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Endothelium; Hyperlipoproteinemia; Triglycerides

Indexed keywords

ACETYLCHOLINE; ANTILIPEMIC AGENT; ARGININE; ATORVASTATIN; CHOLESTEROL; NITROPRUSSIDE SODIUM; SEROTONIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ENDOTHELIUM LESION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VASODILATATION;

EID: 0034098951     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.3.744     Document Type: Article

References (38)

1. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467-471.
2. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med. 1996;334:150-154.
3. Panza JA, Quyyumi AA, Brush-JE J, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
4. Johnstone MT, Creager SJ, Scales KM, Cusco JA, Lee BK, Creager MA. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
5. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol. 1994;24:1468-1474.
6. Lewis TV, Dart AM, Chin DJ. Non-specific inhibition by human lipoproteins of endothelium dependent relaxation in rat aorta may be attributed to lipoprotein phospholipids. Cardiovasc Res. 1997;34: 590-596.
7. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997;79:350-354.
8. Lundman P, Eriksson M, Schenck GK, Karpe F, Tornvall P. Transient triglyceridemia decreases vascular reactivity in young, healthy men without risk factors for coronary heart disease. Circulation. 1997;96: 3266-3268.
9. Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockcroft JR, Brett SE, Ritter JM. Preserved endothelial function in patients with severe hypertriglyceridemia and low functional lipoprotein lipase activity. J Am Coll Cardiol. 1997;29:964-968.
10. Jansen H, Hop W, van Tol A, Bruschke AV, Birkenhager JC. Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis. 1994;107:45-54.
11. Blauw GJ, van Brummelen P, Chang PC, Vermeij P, van Zwieten PA. Arterial and venous effects of serotonin in the forearm of healthy subjects are not age-related. J Cardiovasc Pharmacol. 1989;14:14-21.
12. Redgrave TG, Roberts DC, West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem. 1975;65:42-49.
13. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
14. Bakker Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275: 128-133.
15. Woo KS, Chook P, Lolin YI, Cheung AS,Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997;96: 2542-2544.
16. Gilligan DM, Guetta V, Panza JA, Garcia CE, Quyyumi AA, Cannon RO. Selective loss of microvascular endothelial function in human hypercholesterolemia. Circulation. 1994;90:35-41.
17. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288: 373-376.
18. Bellan JA, McNamara DB, Kadowitz PJ. Differential effects of nitric oxide synthesis inhibitors on vascular resistance and responses to acetylcholine in cats. Am J Physiol. 1993;264:H45-H52.
19. Bruning TA, Chang PC, Kemme MJ, Vermeij P, Pfaffendorf M, van Zwieten PA. Comparison of cholinergic vasodilator responses to acetylcholine and methacholine in the human forearm. Blood Press. 1996;5: 333-341.
20. +]: a functional approach to separating EDHF-and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol. 1993;21: 423-429.
21. Vargas F, Sabio JM, Luna JD. Contribution of endothelium derived relaxing factors to acetylcholine induced vasodilatation in the rat kidney. Cardiovasc Res. 1994;28:1373-1377.
22. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997;100:2793-2799.
23. Najibi S, Cowan CL, Palacino JJ, Cohen RA. Enhanced role of potassium channels in relaxations to acetylcholine in hypercholesterolemic rabbit carotid artery. Am J Physiol. 1994;266:H2061-H2067.
24. Bauersachs J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996;94:3341-3347.
25. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998; 396:269-272.
26. Bruning TA, Chang PC, Blauw GJ, Vermeij P, van Zwieten PA. Serotonin-induced vasodilatation in the human forearm is mediated by the 'nitric oxide-pathway': no evidence for involvement of the 5-HT3-receptor. J Cardiovasc Pharmacol. 1993;22:44-51.
27. Iriyama K, Carpentier YA. Clinical significance of transfer of apolipoproteins between triacylglycerol-rich particles in lipid emulsions and plasma lipoproteins. Nutrition. 1994;10:252-254.
28. Bjorkegren J, Packard CJ, Hamsten A, Bedford D, Caslake MJ, Foster L, Shepherd J, Stewart P, Karpe F. Accumulation of large very low density lipoproteins in plasma during intravenous infusion of chylomicron like triglyceride emulsion reflects competition for a common lipolytic pathway. J Lipid Res. 1996;37:76-86.
29. Plotnick GD, Corretti MC, Vogel RA. Effect of antioxidant vitamins on the transient impairment of endothelium-dependent brachial artery vasoactivity following a single high-fat meal. JAMA. 1997;278:1682-1686.
30. Pfaffendorf M, Bruning TA, Batnik HD, van Zweiten PA. The interaction between methylene blue and the cholinergic system. Br J Pharmacol. 1997;122:95-98.
31. Arnal JF, Munzel T, Venema RC, James NL, Bai CL, Mitch WE, Harrison DG. Interactions between L-arginine and L-glutamine change endothelial NO production: an effect independent of NO synthase substrate availability. J Clin Invest. 1995;95:2565-2572.
32. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor, tetrahydrobiopterin. J Cardiovasc Pharmacol. 1997;29:8-15.
33. Higman DJ, Strachan AM, Buttery L, Hicks RC, Springall DR, Greenhalgh RM, Powell JT. Smoking impairs the activity of endothelial nitric oxide synthase in saphenous vein. Arterioscler Thromb Vasc Biol. 1996;16:546-552.
34. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46.
35. Nagornev VA, Rabinovich VS. Can endothelial cells accumulate lipids? Atherosclerosis. 1998;136:197-198.
36. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97:1446-1452.
37. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998; 97:1440-1445.
38. Laufs U, La FV, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97: 1129-1135.